Pomalive, a formulation of standardized olive and pomegranate fruit extract, may support dyslipidemia, says recent study

The product contains hydroxytyrosol from the olive fruit and punicalagin from the pomegranate fruit, which are polyphenols that have been shown in research to support endothelial function.

A recent study1 found that supplementation with a product combining standardized olive fruit extract and standardized pomegranate fruit extract (Pomalive from Euromed, based in Mollet del Vallès, Spain), may support dyslipidemia. The product contains hydroxytyrosol from the olive fruit and punicalagin from the pomegranate fruit, which are polyphenols that have been shown in research to support endothelial function. The study was conducted by researchers from the Nutrition Department of the University Hospital La Paz, based in Madrid, Spain.

During the twenty-week crossover, randomized, double-blind and placebo-controlled clinical trial, 84 subjects between 45 and 65 years with dyslipidemia were given either Pomalive or placebo for two eight week treatment periods, separated by a four-week wash-out period. At the beginning and end of each 8-week intervention period, fasting blood samples were collected for biochemical analysis total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides.

Results showed that supplementation with active supplement significantly reduced plasma levels of LDL-C in subjects with initially high plasma levels of LDL-C (≥160 mg/dL). No significant effects were found after placebo. At the end of the placebo period, subjects experienced a significant decrease in plasma levels of HDL-C, while supplementation with the Pomalive saw a significant increase in the plasma levels of HDL-C in subjects with initially low plasma levels of HDL-C. Supplementation with Pomalive also significantly decreased plasma TG levels, while placebo had no effect on plasma TG levels.

“In an increasingly ageing society fighting lifestyle diseases such [atherosclerotic vascular disease], we see our natural, sustainably produced and high-purity product as a real contribution to the enhancement of quality of life in later years,” said Andrea Zangara, scientific marketing manager at Euromed, in a press release. “The study results, achieved using gold standard protocols and in collaboration with an authoritative medical institution, provide more evidence on the cardiovascular health-promoting benefits of Pomalive, making it an ideal inclusion in premium dietary supplements, functional foods and pharmaceuticals.”

Reference

  1. Quirós-Fernández, R et al. “Oral supplement containing hydroxytyrosol and punicalagin improves dyslipidemia in an adult population without co-adjuvant treatment: A randomized, double-blind, controlled and crossover trial.” Nutrients, vol. 14, no. 9 (April 29, 2022): 1879, https://doi.org/10.3390/nu14091879